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Purpose or Objective: In patients undergoing surgical 
resection of brain metastasis local recurrence is about 60%. 
Whole brain Radiation Therapy (WBRT) can significantly 
reduce the risk of local relapse but fails to improve overall 
survival. The most important side effects of WBRT are 
neurocognitive deficits, which can reduce quality of life. The 
goal of this study is to evaluate the role of stereotactic 
fractionated radiotherapy (SFRT) in patients with one to 
three brain metastases after surgical resection. 
 
Material and Methods: We performed a retrospective single-
institutional study in 60 patients undergoing SFRT of surgical 
cavity after resection of ≤3 brain metastases (November 2009 
- August 2013). The total irradiation dose was 30 Gy (5Gy/d, 
BED 45 Gy) after complete macroscopical resection and 35 Gy 
(5Gy/d, BED 52.5 Gy) in patients with macroscopic residual 
tumour after surgery. Macroscopic residual tumour was 
defined as contrast enhancement next to the resection cavity 
on the postoperative T1-MRI. We investigated local control 
(LC) as a primary endpoint. Intracranial distant intracranial 
tumour control (DC), overall survival (OS) and side effects 
were secondary endpoints. 
 
Results: The median follow-up for 52 patients was 8 months 
(1 to 32 months). 8 patients were lost to follow-up, due to 
mortality or morbidity. There were 6 (11.5%) local failures 
and 29 (55.8%) distant failures. Local control was correlated 
with age (p=0.046). Thirty-seven of 60 (61.7%) patients died 
during follow-up. Median overall survival was 15 months. Cox 
regression for survival was significant for KPS score ≤ 70% and 
size of PTV. No severe side effects were seen. Patients 
undergoing whole brain radiation therapy (WBRT) as salvage 
therapy in case of progression had no severe side effects. 
 
Conclusion: SFRT could be an alternative to WBRT after 
surgical resection of ≤3 brain metastasis. We had an 
encouraging rate of local control. Due to the high rate of 
distant intracranial failure regular follow-up with MRI is 
mandatory. No Grade 3, 4 or 5 adverse events were reported 
in patients undergoing WBRT or additional Stereotactic 
Radiotherapy as salvage therapy in case of intracranial 
progression. Prospective studies are warranted. 
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Purpose or Objective: Stereotactic body radiotherapy (SBRT) 
of vertebral metastases has emerged as a promising 
methodology, offering high rates of symptom relief and local 
control combined with low risk of toxicity. Nonetheless, local 
failure or spinal instability may occur, generating the need 
for subsequent surgery in the irradiated region. This study 
evaluated whether there is an increased incidence of intra- 
and post-surgical complications after high-dose radiotherapy. 
 
Material and Methods: Based on a retrospective international 
database of 704 cases of SBRT for vertebral metastases, 42 
patients treated at 7 different institutions were identified 
who underwent surgery in a previously stereotactic irradiated 
region. Data regarding surgical characteristics and 
complications were available for 38 patients. 
 
Results: Twenty women, 13 men, median age 59 years (range 
27 to 84 years) underwent SBRT for vertebral metastases 
followed by surgery. In 18 cases, conventional radiotherapy 
had been delivered prior to SBRT at a median dose of 30 Gy 
in median 10 fractions. SBRT was most frequently 
administered in 1 fraction with a mean prescription dose of 
20,9 Gy (mean EQD2/10 = 45,3Gy). The median time until the 
surgical intervention was performed was 7.5 months after 
SBRT. The most frequent reason for surgery was progressive 
pain (n=35) followed by progressive neurological 
deterioration (N=20) or fracture of the vertebral body (n=16). 
Therefore, open surgical decompression (n=29) and/or 
stabilization (n=22) were the most frequently performed 
surgical procedures. Increased fibrosis complicating the 
operation was explicitly stated in the surgical report in 5 
cases. In 3 patients a durotomy occurred which could be 
sufficiently sealed during the operation in two cases and 
required surgical revision in 1 case. Median blood loss was 
425 ml, but 5 patients had a blood loss of >1l during the 
procedure. After the operation, 2 patients suffered from an 
increased neurological deficit which could be explained by an 
epidural hematoma in one case. Delayed wound healing was 
reported in 4 cases. In one patient this lasted for 5 months 
after surgery until death. One patient died shortly after the 
surgical procedure due to unknown causes. 
 
Conclusion: In this largest series of surgical interventions 
following spine SBRT, the overall complication rate was 45%. 
This appears to be higher when compared to primary surgery 
without previous SBRT. Therefore, spine surgery after SBRT is 
technically feasible. However, the decision to perform 
surgical procedures in these highly complex cases should be 
made by a multidisciplinary team and their performance in 
an experienced center may be beneficial. 
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Purpose or Objective: Hypofractionated Stereotactic 
radiosurgery (HSRS) delivered in few fractions, up to 5, has 
been employed in patients with large brain metastases (BM), 
alone or after surgical resection on tumor bed, as an 
alternative to whole brain radiotherapy or to single fraction 
SRS with the aim to reduce late radiation-induced toxicity 
while maintaining high local control rate. The aim of this 
study was to evaluate the outcome and toxicity of patients 
treated for large brain metastases using HSRS, in terms of 
local control, incidence of distant brain metastases (DBM) 
and toxicity  
 
S306                                                                                                                                                    ESTRO 35 2016 
______________________________________________________________________________________________________ 
Material and Methods: Between July 20011 and July 2015, 
138 patients, 66 men and 72 women, with large brain 
metastases from different solid tumors have been treated 
with HSRT, using Volumetric Modulated Arc Therapy Rapid-
Arc (VMAT-RA) in flattening filter-free (FFF) beams mode. 
The total doses prescribed were 30 Gy in 3 fractions or 30 Gy 
in 5 fractions in relation to the size and site of BM or 30 Gy in 
3 fractions on tumor bed in patients underwent surgical 
resection. 
 
Results: At a median follow-up time of 10.6 months ( range 
2-53 months) 6 (4%) patients had local relapse at a median 
time of 8 months (range 2-53 months) and 45 (32%) patients 
distant brain progression at a median time of 8 months (range 
2-26 months). The 1- and 2-year local control rates were 90% 
and 87% respectively. The 1- and 2-year survival rates were 
72% and 42 % respectively. At the last observation time 99 
/71.7%) patients were alive and 39 (28.3%) dead. Eighty-five 
percent of patients succumbed to their extracranial disease 
and 15% died of progressive intracranial disease. During HSRS 
no increases of corticosteroid or AED have been needed. No 
symptomatic radionecrosis was observed. Factors recorded as 
influencing local failure and worse survival were the presence 
of metastases at diagnosis, NSCLC histology and impossibility 
to surgical resection  
 
Conclusion: HSRS is a safe and effective treatment option for 
patients with large brain metastases. In our series better 
local control was recorded in case of metachronous BM, 
breast cancer histology and patients suitable for surgical 
resection followed by HSRT. 
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Purpose or Objective: To retrospectively evaluate safety and 
brain control (BC) in patients (pts) with 1-4 brain metastases 
(BM) from renal cell carcinoma (RCC) submitted to 
radiosurgery (RS) or fractionated stereotactic radiotherapy 
(FSRT) with or without target therapies (TTs). 
 
Material and Methods: 46 pts with 74 BM were treated. 
Male/female ratio was 31/15, median age was 62y (range, 
29-76). Median KPS was 100% (range, 50-100), 14 (37%), 27 
(59%) and 2 (4%) pts were in RPA class 1, 2 and 3, 
respectively, and 37 (80%) pts had extracranial metastases. 
Disease was controlled in 28 (61%) and in progression in 18 
(39%) pts. Neurologic functional score was generally good 
(NFS=0-2) having only 5 (11%) NFS=3. Relapse was defined 
“in-field” when more than 95% of the recurrence volume was 
within the original 50% isodose, and “out-field” in the other 
cases. Median number of irradiated BM per patient was 1 
(range, 1-4). 37 (80%) pts with 63 BM (85%) received RS at a 
median dose of 20Gy (range, 15-25). Remaining 9 (20%) with 
11 lesions (15%) were underwent FSRT at a dose of 5x6-7Gy. 
21 (46%) pts did not receive TTs, 19 (46%) received 
concomitant and 6 (8%) post- irradiation TTs (sunitinib, 
sorafenib, pazopanib, mTOR inibitors, bevacizumab). 
 
Results: At a median follow-up of 19 months (range, 1-51), 
41 (89%) pts with 66 (89%) BM were evaluable. Local control 
was obtained in 96% of BM: there were complete remission in 
29 (44%), partial remission in 25 (38%), stable disease in 9 
(14%), and progression in 3 (4%) BM. During follow up, 21 
(51%) pts had no brain progression, 4 (10%) had in-field 
relapse, 15 (37%) out-field relapse, and 1 (2%) in- and out-
field relapse. Of 20 (49%) relapsing pts, 14 (70%) were 
retreated with RS, surgery, WBRT and FSRT (8, 3, 2 and 1, 
respectively). In-field relapse occurred after a median time 
of 21.5, out-field relapse after a median time of 8 months. At 
the time of analysis, 39/41 pts (95%) had died, 9 (22%) for 
brain progression, 30 (73%) for systemic progression. Global 
median duration of BC was 22 months (range, 3-51) and 
global median OS from irradiation was 19 months (range, 4-
53). No difference in outcome and toxicity was registered 
comparing pts receiving or not TTs. Deaths due to brain or 
systemic progression occurred after a median time of 12 and 
20 months, respectively. 
 
Conclusion: Effectiveness of RS and FSRT in RCC BM was 
confirmed. The addition of concomitant TTs, though safety, 
does not seem to improve outcomes.  
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Purpose or Objective: to evaluate the local control and 
survival in patients with brain metastases treated with 
stereotactic radiosurgery (SRS) as primary treatment 
approach and to identify predictors of distant brain failure 
(DBF) 
 
Material and Methods: from 2010 to 2014 three hundred and 
eleven brain metastases in 204 consecutive patients were 
treated with SRS at University of Turin. Patients eligible for 
SRS had one to five brain lesions, metastases size ≤ 3 cm, 
Karnofsky performance status ≥ 70 and life expectancy ≥ 3 
months. A total of 172 patients with 266 brain metastases 
were analysed. Doses ranged from 18-24 Gy in single fraction 
related to lesion size. Local control (LC), overall survival (OS) 
and distant brain failure were estimated using the Kaplan-
Meier method. Univariate and multivariate analysis were 
performed to determine the prognostic factors for treatment 
outcomes and DBF 
 
Results: the median follow-up was 24.9 months. The 6- and 
12- month local control rates were 88.5% and 75.1% 
respectively. 46 patients recurred locally after SRS on 55 
brain metastases, with a median time to local failure of 12.1 
months. The median overall survival was 12.8 months, with 
6- and 12- months OS rates of 74.5% and 53.8% respectively. 
On multivariate analysis, no significant prognostic factors 
were associated with local control and survival outcome, 
even if RPA class (I versus II) and metastases diameter 
showed a trend of significance for OS (p=0.11 e p=0.10 
respectively). A distant brain failure was observed in 88 
patients (43.2%), with a median time to DBF of 5.5 months. 
60.8% of these patients maintained an oligometastatic 
intracranial disease (≤ 5 brain lesions ), while 39.2% of 
patients developed multiple brain metastases. Salvage 
therapy was delivered in 46.5% of DBF patients, consisting of 
WBRT in 28.4% of cases and SRS on metastases of new onset 
in 18.1% of patients. However, more than half of patients 
with DBF (53.5%) did not require any salvage treatment. 
Prognostic factors significantly associated with prolonged 
DBF-free survival on multivariate analysis included the 
number of brain metastases <2 (p=0.000) and breast primary 
(p=0.026). Tumor size ≤ 10 mm, s table extracranial disease 
and oligometastatic brain failure were significant predictive 
factors for survival after DBF. 
 
Conclusion: stereotactic radiosurgery is an effective and 
well-tolerated treatment option in patients with 
oligometastatic disease. SRS might also represent a valid 
salvage strategy in patients relapsing in order to delay or 
completely avoid WBRT.  
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